Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4 and Insertion of the selection cassette in exon4.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-FHL1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The FHL1 protein also known as Four and a Half LIM Domains 1 operates mechanically as a multifunctional adaptor protein. Its molecular mass is approximately 35 kDa. This protein is widely expressed in skeletal muscle and heart tissues playing a role in various cellular contexts. FHL1 interacts within the cell cytoplasm and nucleus allowing it to assist in multiple cellular processes.
Biological function summary
FHL1 integrates into diverse cellular mechanisms by engaging in protein-protein interactions. It acts as part of complexes that regulate transcription cell differentiation and development. The involvement of FHL1 in muscle growth and maintenance is significant partly due to its expression pattern. In skeletal muscles it helps adapt muscle response to mechanical stress while in cardiac tissue it participates in muscle contractility and integrity.
Pathways
FHL1 plays important roles in both the muscle differentiation pathway and the MAPK/ERK signaling pathway. It influences the transcriptional regulation essential for muscle cell growth and differentiation. FHL1 interacts with proteins such as MyoD during muscle formation and MEF2 in the MAPK/ERK pathway modulating cellular responses to external signals and stressors.
FHL1's involvement is evident in conditions such as Emery-Dreifuss muscular dystrophy and cardiomyopathy. Mutations or dysregulation of this protein can impair muscle function leading to myopathy. It associates with other proteins like emerin in genetic disorders affecting muscle tissues and structural integrity revealing its vital role in maintaining muscular health.
